Schroder Investment Management Group
KRYS icon

Schroder Investment Management Group’s Krystal Biotech KRYS Stock Holding History

Schroder Investment Management Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,170
Closed -$1.8M – 1182
2025
Q3 		$1.8M Sell
10,170
-58
-0.6% -$8.68K ﹤0.01% 950
2025
Q2 		$1.41M Sell
10,228
-2,820
-22% -$414K ﹤0.01% 959
2025
Q1 		$2.4M Buy
13,048
+441
+3% +$74.2K ﹤0.01% 886
2024
Q4 		$2.01M Hold
12,607
– – ﹤0.01% 922
2024
Q3 		$2.23M Sell
12,607
-27,773
-69% -$5.36M ﹤0.01% 925
2024
Q2 		$7.42M Buy
40,380
+896
+2% +$150K 0.01% 696
2024
Q1 		$7.03M Sell
39,484
-35,461
-47% -$4.93M 0.01% 720
2023
Q4 		$9.3M Buy
+74,945
New +$8.31M 0.01% 644

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schroder Investment Management Group's KRYS Position: Q4 2025 in Review

Schroder Investment Management Group sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 10,170 shares — an estimated $1.8M sold.

Schroder Investment Management Group first reported a position in KRYS in Q4 2023 and held it in 8 quarters. The position peaked at $9.3M in Q4 2023. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • Schroder Investment Management Group reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 10,170 Krystal Biotech shares in Q4 2025, an estimated $1.8M.
  • Schroder Investment Management Group first reported a position in Krystal Biotech in Q4 2023 and held it in 8 quarters.
  • Schroder Investment Management Group's Krystal Biotech position peaked at $9.3M in Q4 2023.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.